HGS-ETR1: Phase I interim data

In an ongoing open-label, dose-escalation Phase I trial, HGS-ETR1 was well tolerated in 37 patients over dose levels of 0.01-10.0 µg/kg. Data were presented at the American Society of Clinical Oncolog...